Literature DB >> 25477569

Tedizolid phosphate.

Dennis J Cada1, Kyle Ingram2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The November 2014 monograph topics are suvorexant, idelalisib, belinostat for injection, C1 esterase inhibitor, and ledipasvir. The DUE/MUE is on suvorexant.

Entities:  

Year:  2014        PMID： 25477569      PMCID： PMC4252220          DOI： 10.1310/hpj4910-961

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

1.  Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

Authors:  Carmen Betriu; Gracia Morales; Icíar Rodríguez-Avial; Esther Culebras; María Gómez; Fátima López-Fabal; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Rodrigo E Mendes; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

3.  Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2009-01-22       Impact factor: 5.790

4.  Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Authors:  Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Gregory J Moran; Edward Fang; G Ralph Corey; Anita F Das; Carisa De Anda; Philippe Prokocimer
Journal:  Lancet Infect Dis       Date:  2014-06-05       Impact factor: 25.071

6.  Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

7.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

8.  Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.

Authors:  Voon Ong; Shawn Flanagan; Edward Fang; Howard J Dreskin; Jeffrey B Locke; Kenneth Bartizal; Philippe Prokocimer
Journal:  Drug Metab Dispos       Date:  2014-05-29       Impact factor: 3.922

9.  In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

Authors:  K J Shaw; S Poppe; R Schaadt; V Brown-Driver; J Finn; C M Pillar; D Shinabarger; G Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

10.  In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Authors:  Ronda Schaadt; Debora Sweeney; Dean Shinabarger; Gary Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191
View more
  2 in total

1.  Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.

Authors:  Merve Karpuz; Evren Atlihan-Gundogdu; E Selin Demir; Zeynep Senyigit
Journal:  AAPS PharmSciTech       Date:  2021-02-02       Impact factor: 3.246

2.  Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation.

Authors:  Alaa Emad Eldeeb; Salwa Salah; Mostafa Mabrouk; Mohammed S Amer; Nermeen A Elkasabgy
Journal:  Pharmaceutics       Date:  2022-01-24       Impact factor: 6.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.